Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. (Q39845365)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

0 references

0 references

Frédéric Clement

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Patricia Bourguignon

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Isabel Leroux-Roels

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Marguerite Koutsoukos

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sophia Steyaert

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Michel Janssens

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Kristen Cohen

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Pierre Vandepapelière

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Louise Pedneault

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Lisa McNally

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Gerald Voss

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Geert Leroux-Roels

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

0 references

publication date

20 August 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

7016-7024

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

43

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Scientific and policy challenges to development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

CD8 lethargy in the absence of CD4 help.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Vaccine adjuvants revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV vaccines: new frontiers in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Follicular helper T cells as cognate regulators of B cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Lymphocyte Subsets in Normal Human Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Mechanism of antigen-driven selection in germinal centres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Signals that influence T follicular helper cell differentiation and function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV preferentially infects HIV-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Progress in defining CD4 helper cell responses in chronic viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

HIV T cell vaccines, the importance of clades

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

An HIV vaccine--evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Antibody-based HIV-1 vaccines: recent developments and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Estimated Global Distribution and Regional Spread of HIV-1 Genetic Subtypes in the Year 2000

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

based on heuristic

inferred from DOI database lookup

1 Statistical analysis of radioligand assay data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.08.035

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

release_ie4vbrqpenhd3lhanpybwctcxq

1 reference

https://api.fatcat.wiki/v0/release/ie4vbrqpenhd3lhanpybwctcxq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20728522%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39845365&oldid=2091399108"